Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advertisement
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
View More
Tian Zhang, MDAdvanced Renal Cell Carcinoma | June 10, 2024
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
GU Oncology Now EditorsAdvancements in Oncology | June 6, 2024
The discussion focused on advanced and metastatic stages of RCC, shedding light on current practices in clinics.
Manmeet Ahluwalia, MD, MBA, FASCOAdvanced Renal Cell Carcinoma | June 10, 2024
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
Brandon TwyfordAdvanced Renal Cell Carcinoma | June 10, 2024
The KEYNOTE-426 study explored pembrolizumab and axitinib vs sunitinib in advanced RCC using genetic biomarkers.
Karl Semaan, MDAdvanced Renal Cell Carcinoma | June 5, 2024
Drs. Semaan and El Zarif detail an investigation into first-line systemic therapy following adjuvant immunotherapy for RCC.
Viktor Grünwald, MD, PhDAdvanced Renal Cell Carcinoma | June 5, 2024
Dr. Grünwald showcases patterns of progression and subsequent therapy for patients receiving len/pembro for aRCC.
Emily MenendezAdvanced Renal Cell Carcinoma | June 10, 2024
The trial previously demonstrated longer PFS rates with avelumab plus axitinib in patients with PD-L1-positive tumors.
Emily MenendezAdvanced Renal Cell Carcinoma | June 10, 2024
Patients who received lenvatinib plus pembrolizumab experienced later progression across tumors in multiple organs.
Zachary BessetteAdvanced Renal Cell Carcinoma | June 10, 2024
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Katy MarshallAdvanced Renal Cell Carcinoma | June 7, 2024
Investigators found that the median follow-up period was 16.5 months at the study’s cutoff date.
Katy MarshallAdvanced Renal Cell Carcinoma | May 16, 2024
Overall survival, TFS, TFS with and without toxicity, and time to all protocol therapy cessation were quantified.
Zachary BessetteAdvanced Renal Cell Carcinoma | May 4, 2024
ICIs improves OS for patients with mRCC and sarcomatoid features who undergo CN, regardless of the timing of surgery.
Emily MenendezAdvanced Renal Cell Carcinoma | May 3, 2024
Researchers completed a comprehensive evaluation of features that can serve as biomarkers of response to ICB therapy in mRCC.
Katy MarshallAdvanced Renal Cell Carcinoma | May 1, 2024
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
Umang Swami MD, MSAdvanced Renal Cell Carcinoma | May 1, 2024
Dr. Swami investigated the efficacy of cabozantinib in combination with immune checkpoint inhibitors for mccRCC.
Yousef Zakharia, MDAdvanced Renal Cell Carcinoma | April 25, 2024
Dr. Zakharia continues his commentary on the BTCRC-GU16-043 study investigating guadecitabine and durvalumab in accRCC.
Yousef Zakharia, MDAdvanced Renal Cell Carcinoma | April 25, 2024
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
Advertisement
Advertisement
Advertisement